See more : Loop Telecommunication International,Inc. (3025.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Abbott Laboratories (ABT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbott Laboratories, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- DuoLun Technology Corporation Ltd. (603528.SS) Income Statement Analysis – Financial Results
- ItN Nanovation AG (I7N.DE) Income Statement Analysis – Financial Results
- Cashmere Valley Bank (CSHX) Income Statement Analysis – Financial Results
- Saturn Oil & Gas Inc. (SOIL.V) Income Statement Analysis – Financial Results
- Pharmosa Biopharm Inc. (6875.TWO) Income Statement Analysis – Financial Results
Abbott Laboratories (ABT)
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B | 21.85B | 39.87B | 38.85B | 35.17B | 30.77B | 29.53B | 25.91B | 22.48B | 22.34B | 19.68B | 19.68B | 17.68B | 16.29B | 13.75B | 13.18B | 12.48B | 11.88B | 11.01B | 10.01B | 9.16B | 8.41B | 7.85B | 6.88B | 6.16B | 5.38B | 4.94B | 4.39B | 3.81B | 3.36B |
| Cost of Revenue | 17.98B | 19.14B | 18.54B | 15.00B | 13.23B | 12.71B | 12.34B | 9.02B | 8.75B | 9.22B | 10.04B | 15.12B | 15.54B | 14.67B | 13.21B | 12.61B | 11.42B | 9.82B | 10.64B | 8.88B | 9.47B | 8.51B | 7.75B | 6.24B | 5.98B | 5.39B | 5.05B | 4.73B | 4.33B | 3.99B | 3.68B | 3.08B | 2.76B | 2.55B | 2.25B | 2.08B | 1.86B | 1.67B | 1.54B |
| Gross Profit | 22.13B | 24.51B | 24.54B | 19.61B | 18.67B | 17.87B | 15.05B | 11.83B | 11.66B | 11.03B | 11.81B | 24.75B | 23.31B | 20.50B | 17.56B | 16.92B | 14.49B | 12.66B | 11.70B | 10.80B | 10.21B | 9.18B | 8.54B | 7.51B | 7.20B | 7.08B | 6.84B | 6.28B | 5.69B | 5.16B | 4.72B | 4.77B | 4.12B | 3.60B | 3.13B | 2.85B | 2.53B | 2.14B | 1.82B |
| Gross Profit Ratio | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.96% | 56.73% | 57.13% | 54.47% | 54.05% | 62.08% | 60.00% | 58.30% | 57.06% | 57.29% | 55.92% | 56.33% | 52.36% | 54.86% | 51.86% | 51.90% | 52.42% | 54.61% | 54.64% | 56.77% | 57.54% | 57.03% | 56.79% | 56.38% | 56.18% | 60.81% | 59.85% | 58.53% | 58.19% | 57.82% | 57.65% | 56.17% | 54.19% |
| Research & Development | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.24B | 1.42B | 1.41B | 1.35B | 1.45B | 4.32B | 4.80B | 3.73B | 2.74B | 2.69B | 2.51B | 2.26B | 1.82B | 1.70B | 1.73B | 1.56B | 1.58B | 1.35B | 1.19B | 1.22B | 1.30B | 1.20B | 1.07B | 963.52M | 880.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -495.00K | -817.00K | -324.00K | 96.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.95B | 11.25B | 11.32B | 9.70B | 9.77B | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Other Expenses | 1.97B | 2.01B | 2.05B | 2.13B | 1.94B | 139.00M | 1.25B | -945.00M | 281.00M | -14.00M | 32.00M | 34.00M | -119.00M | 62.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -138.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -70.00M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| Operating Expenses | 15.66B | 16.15B | 16.11B | 14.25B | 14.14B | 14.22B | 13.33B | 8.64B | 8.79B | 8.43B | 9.18B | 16.38B | 17.56B | 14.10B | 11.15B | 11.12B | 9.91B | 8.60B | 7.32B | 6.62B | 6.78B | 5.54B | 5.31B | 4.11B | 4.05B | 3.97B | 3.99B | 3.66B | 3.30B | 3.02B | 2.80B | 3.25B | 2.56B | 2.20B | 1.91B | 1.75B | 1.52B | 1.26B | 1.08B |
| Cost & Expenses | 33.63B | 35.29B | 34.65B | 29.25B | 27.37B | 26.93B | 25.66B | 17.67B | 17.54B | 17.65B | 19.22B | 31.50B | 33.10B | 28.77B | 24.36B | 23.74B | 21.34B | 18.42B | 17.96B | 15.50B | 16.26B | 14.05B | 13.06B | 10.35B | 10.03B | 9.36B | 9.03B | 8.40B | 7.63B | 7.01B | 6.48B | 6.33B | 5.32B | 4.75B | 4.16B | 3.84B | 3.38B | 2.93B | 2.62B |
| Interest Income | 385.00M | 183.00M | 43.00M | 46.00M | 94.00M | 105.00M | 124.00M | 99.00M | 105.00M | 77.00M | 67.00M | 79.23M | 85.20M | 105.45M | 137.78M | 201.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 637.00M | 375.00M | 490.00M | 500.00M | 576.00M | 721.00M | 780.00M | 332.00M | 58.00M | 73.00M | 90.00M | 513.00M | 530.14M | 553.14M | 382.00M | 528.47M | 593.14M | 292.35M | 153.66M | 149.09M | 146.12M | 205.22M | 234.76B | 23.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 601.00M | 555.00M | 791.00M | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.27B | 1.18B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M | 566.42M | 510.50M | 484.08M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| EBITDA | 10.61B | 12.38B | 12.74B | 8.79B | 7.77B | 7.12B | 6.13B | 3.07B | 4.83B | 4.22B | 3.45B | 3.50B | 9.26B | 9.14B | 9.49B | 8.22B | 6.43B | 4.25B | 6.22B | 5.61B | 4.20B | 4.30B | 4.39B | 3.40B | 3.98B | 3.90B | 3.56B | 3.30B | 2.95B | 2.65B | 2.41B | 1.95B | 1.94B | 1.76B | 1.53B | 1.37B | 1.25B | 1.08B | 892.90M |
| EBITDA Ratio | 26.44% | 24.50% | 24.95% | 21.94% | 20.87% | 19.51% | 18.08% | 13.38% | 18.37% | 15.51% | 15.80% | 21.08% | 15.08% | 19.30% | 20.82% | 21.20% | 25.41% | 33.72% | 23.92% | 27.28% | 21.54% | 25.87% | 33.77% | 26.56% | 27.68% | 29.46% | 28.54% | 29.05% | 29.16% | 28.61% | 27.38% | 21.50% | 27.41% | 28.02% | 27.53% | 27.03% | 28.27% | 27.62% | 24.92% |
| Operating Income | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.73B | 3.19B | 2.87B | 2.60B | 2.63B | 8.09B | 5.75B | 6.09B | 6.24B | 5.69B | 4.58B | 2.04B | 4.36B | 3.90B | 3.32B | 3.53B | 1.89B | 3.40B | 3.15B | 3.12B | 2.85B | 2.62B | 2.38B | 2.14B | 1.92B | 1.53B | 1.56B | 1.41B | 1.22B | 1.10B | 1.01B | 878.60M | 737.10M |
| Operating Income Ratio | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 6.30% | 15.27% | 14.05% | 12.84% | 12.03% | 20.28% | 14.81% | 17.31% | 20.27% | 19.28% | 17.67% | 9.09% | 19.53% | 19.81% | 16.88% | 19.96% | 11.63% | 24.74% | 23.90% | 24.99% | 23.99% | 23.76% | 23.80% | 23.42% | 22.88% | 19.43% | 22.64% | 22.83% | 22.70% | 22.32% | 22.92% | 23.07% | 21.94% |
| Total Other Income/Expenses | 186.00M | -56.00M | -214.00M | -389.00M | -455.00M | -777.00M | 667.00M | -1.61B | 316.00M | -81.00M | -92.00M | -1.22B | -553.36M | -374.75M | 958.03M | 162.45M | -108.90M | 234.15M | 257.65M | 227.28M | 411.89M | 143.27M | -10.88M | 415.83M | 247.53M | 123.98M | 84.17M | 52.44M | 12.42M | 22.48M | 19.26M | 212.80M | -12.80M | -55.30M | -27.00M | -46.60M | -68.50M | -59.90M | -42.60M |
| Income Before Tax | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.52B | 6.26B | 5.20B | 5.71B | 7.19B | 5.86B | 4.47B | 2.28B | 4.62B | 4.13B | 3.73B | 3.67B | 1.88B | 3.82B | 3.40B | 3.24B | 2.95B | 2.67B | 2.40B | 2.17B | 1.94B | 1.74B | 1.54B | 1.35B | 1.19B | 1.06B | 937.20M | 818.70M | 694.50M |
| Income Before Tax Ratio | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% | 9.40% | 8.15% | 6.78% | 15.60% | 12.44% | 11.54% | 15.71% | 13.38% | 16.25% | 23.38% | 19.83% | 17.25% | 10.13% | 20.68% | 20.96% | 18.98% | 20.77% | 11.56% | 27.76% | 25.78% | 25.97% | 24.82% | 24.24% | 23.92% | 23.66% | 23.11% | 22.14% | 22.46% | 21.93% | 22.20% | 21.38% | 21.36% | 21.50% | 20.67% |
| Income Tax Expense | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M | 577.00M | 797.00M | 138.00M | 300.00M | 470.00M | 1.09B | 1.45B | 1.12B | 863.33M | 559.62M | 1.25B | 949.76M | 981.18M | 879.71M | 332.76M | 1.03B | 951.13M | 907.37M | 855.48M | 787.52M | 706.62M | 650.01M | 544.10M | 499.70M | 455.50M | 385.00M | 334.40M | 303.40M | 304.60M | 278.20M | 229.20M |
| Net Income | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B | 4.42B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.88B | 3.61B | 1.72B | 3.37B | 3.24B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B | 1.69B | 1.52B | 1.40B | 1.24B | 1.09B | 965.80M | 859.80M | 752.00M | 632.60M | 540.50M | 465.30M |
| Net Income Ratio | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 11.79% | 14.95% | 12.17% | 13.15% | 18.68% | 16.53% | 13.92% | 7.64% | 15.10% | 16.44% | 13.99% | 15.80% | 9.52% | 20.27% | 18.56% | 18.71% | 17.50% | 17.09% | 16.87% | 16.56% | 16.64% | 15.78% | 15.83% | 15.68% | 15.98% | 15.23% | 14.42% | 14.20% | 13.85% |
| EPS | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 | 1.66 | 3.78 | 3.01 | 2.99 | 3.72 | 3.16 | 2.34 | 1.12 | 2.17 | 2.07 | 1.76 | 1.79 | 1.00 | 1.80 | 1.59 | 1.52 | 1.35 | 1.21 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| EPS Diluted | 3.27 | 3.91 | 3.94 | 2.50 | 2.06 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.75 | 3.01 | 2.97 | 3.70 | 3.13 | 2.31 | 1.12 | 2.16 | 2.06 | 1.75 | 1.78 | 0.99 | 1.78 | 1.57 | 1.49 | 1.33 | 1.19 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| Weighted Avg Shares Out | 1.73B | 1.75B | 1.78B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B | 1.47B | 1.51B | 1.55B | 1.58B | 1.57B | 1.55B | 1.55B | 1.54B | 1.54B | 1.53B | 1.55B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.54B | 1.54B | 1.55B | 1.56B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
| Weighted Avg Shares Out (Dil) | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B | 1.54B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.56B | 1.56B | 1.58B | 1.58B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
3 Dividend Growth Stocks You Can Buy and Hold Forever
These healthcare stocks have fantastic dividend track records.
FeganScott Launches Investigation into Abbott Laboratories Employees Credit Union Data Breach
CHICAGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Attorneys at the law firm FeganScott have launched an investigation into the Abbott Laboratories Employees Credit Union (ALEC) data breach, which, according to company reports, occurred during an August cyberattack against the Illinois-based...
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their...
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott Laboratories: Promising Growth, Yet Fully Valued; A Wait-And-Watch Stock
Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% revenue growth in terms of pure organic sales, with several of its segments...
MDT vs. ABT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
What Drove Abbott's Q3?
Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations. The company reported revenue of $10.64 billion and earnings of $1.21 on a per-share and adjusted basis, compared to our estimates of $10.55 billion...
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Abbott Laboratories is a diversified healthcare company with strong segments, particularly Medical Devices, contributing to steady growth and consistent dividends. ABT's Q2 earnings showed solid performance, with Medical Devices leading organic revenue growth, despite some segments facing challenges including discontinuing...
Source: https://incomestatements.info
Category: Stock Reports